Literature DB >> 19140842

Overview of regular dialysis treatment in Japan as of 31 December 2006.

Shigeru Nakai1, Ikuto Masakane, Takashi Akiba, Takashi Shigematsu, Kunihiro Yamagata, Yuzo Watanabe, Kunitoshi Iseki, Noritomo Itami, Toshio Shinoda, Kunio Morozumi, Tetsuo Shoji, Seiji Marubayashi, Osamu Morita, Naoki Kimata, Tatsuya Shoji, Kazuyuki Suzuki, Kenji Tsuchida, Hidetomo Nakamoto, Takayuki Hamano, Akihiro Yamashita, Kenji Wakai, Atsushi Wada, Yoshiharu Tsubakihara.   

Abstract

A statistical survey of dialysis patients for the year 2006 was carried out for 4051 medical facilities across Japan, and responses were received from 3985 (98.37%) facilities. There were 264 473 dialysis patients (including 9003 peritoneal dialysis patients) in Japan at the end of 2006, which showed an increase of 6708 (2.6%) from the end of 2005. The number of patients per million population was 2069.9. The crude mortality rate during 2006 was 9.2%. The mean age of the patients who began dialysis (in 2006) was 66.4 years, and the mean age of the entire dialysis population was 64.4 years. The primary renal diseases of the patients who began dialysis were diabetic nephropathy (42.9%), chronic glomerulonephritis (25.6%), and nephrosclerosis (9.4%). Of the 3488 facilities that participated in the survey on the dialysate water quality, 2873 facilities (82.4%) measured the endotoxin concentration in the dialysate; and 1197 facilities (37.1%) out of 3228 measured the bacterial count in the dialysate. The mean hemoglobin concentration in the dialysis population at the end of 2006 was 10.23 +/- 1.33 g/dL, which was equal to that at the end of 2005 (10.23 +/- 1.37 g/dL). The mean concentration of serum creatinine in 15 853 patients who started dialysis during 2006 was 8.37 +/- 3.58 mg/dL. The estimated glomerular filtration rate, which was calculated with formula modified for the Japanese population from the Modification of Diet in Renal Disease (MDRD) Study equation, was 5.46 +/- 6.60 mL/min/1.73 m(2).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19140842     DOI: 10.1111/j.1744-9987.2008.00634.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  15 in total

1.  Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents.

Authors:  Terumasa Hayashi; Tomonori Kimura; Keiko Yasuda; Yoshitsugu Obi; Koichi Sasaki; Kenichiro Iio; Kenro Miyasato; Taro Kamimura; Harumi Kitamura; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2012-10-26       Impact factor: 2.801

2.  Diabetics on hemodialysis in El-Minia Governorate, Upper Egypt: five-year study.

Authors:  Osama El-Minshawy; Emad G Kamel
Journal:  Int Urol Nephrol       Date:  2010-03-09       Impact factor: 2.370

3.  Etiology of renal failure influences the outcome of heart valve replacement in chronic dialysis patients.

Authors:  Naoki Washiyama; Norihiko Shiiya; Katsushi Yamashita; Hitoshi Terada; Kazuhiro Ohkura; Kayoko Takahashi
Journal:  J Artif Organs       Date:  2011-01-13       Impact factor: 1.731

4.  Overexpression of miR-34c inhibits high glucose-induced apoptosis in podocytes by targeting Notch signaling pathways.

Authors:  Xiang-Dong Liu; Lian-Yun Zhang; Tie-Chui Zhu; Rui-Fang Zhang; Shu-Long Wang; Yan Bao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Overexpression of acetyl-coenzyme A carboxylase beta increases proinflammatory cytokines in cultured human renal proximal tubular epithelial cells.

Authors:  Masa-aki Kobayashi; Hirotaka Watada; Ryuzo Kawamori; Shiro Maeda
Journal:  Clin Exp Nephrol       Date:  2010-06-01       Impact factor: 2.801

6.  Coronary calcification in patients with chronic kidney disease and coronary artery disease.

Authors:  Satoko Nakamura; Hatsue Ishibashi-Ueda; Sinichiro Niizuma; Fumiki Yoshihara; Takeshi Horio; Yuhei Kawano
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

7.  A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes.

Authors:  Shiro Maeda; Masa-aki Kobayashi; Shin-ichi Araki; Tetsuya Babazono; Barry I Freedman; Meredith A Bostrom; Jessica N Cooke; Masao Toyoda; Tomoya Umezono; Lise Tarnow; Torben Hansen; Peter Gaede; Anders Jorsal; Daniel P K Ng; Minoru Ikeda; Toru Yanagimoto; Tatsuhiko Tsunoda; Hiroyuki Unoki; Koichi Kawai; Masahito Imanishi; Daisuke Suzuki; Hyoung Doo Shin; Kyong Soo Park; Atsunori Kashiwagi; Yasuhiko Iwamoto; Kohei Kaku; Ryuzo Kawamori; Hans-Henrik Parving; Donald W Bowden; Oluf Pedersen; Yusuke Nakamura
Journal:  PLoS Genet       Date:  2010-02-12       Impact factor: 5.917

8.  Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes.

Authors:  Shiro Maeda; Shin-Ichi Araki; Tetsuya Babazono; Masao Toyoda; Tomoya Umezono; Koichi Kawai; Masahito Imanishi; Takashi Uzu; Hirotaka Watada; Daisuke Suzuki; Atsunori Kashiwagi; Yasuhiko Iwamoto; Kohei Kaku; Ryuzo Kawamori; Yusuke Nakamura
Journal:  Diabetes       Date:  2010-05-11       Impact factor: 9.461

9.  Quantitative and qualitative urinary cellular patterns correlate with progression of murine glomerulonephritis.

Authors:  Junpei Kimura; Osamu Ichii; Saori Otsuka; Tomonori Kanazawa; Yuka Namiki; Yoshiharu Hashimoto; Yasuhiro Kon
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

10.  A single nucleotide polymorphism in KCNQ1 is associated with susceptibility to diabetic nephropathy in japanese subjects with type 2 diabetes.

Authors:  Toshihiko Ohshige; Yasushi Tanaka; Shin-ichi Araki; Tetsuya Babazono; Masao Toyoda; Tomoya Umezono; Hirotaka Watada; Daisuke Suzuki; Yasuhiko Iwamoto; Ryuzo Kawamori; Yusuke Nakamura; Shiro Maeda
Journal:  Diabetes Care       Date:  2010-01-07       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.